Peptidomimetic

A peptidomimetic keeps the spatial arrangement of side chains a receptor or enzyme recognises while abandoning some or all of the backbone that carries them. The range runs from modified backbones — an amide reversed, a peptide bond replaced by a non-cleavable isostere — through constrained scaffolds that lock a beta turn, to non-peptide small molecules that share no chemical resemblance to the parent and were found by screening rather than analog design.

HIV protease inhibitors such as saquinavir and ritonavir were built as transition-state mimetics of the peptide substrate the enzyme cleaves, and are dosed orally. On the receptor side, MK-677 is an orally active spiroindoline that agonises the ghrelin receptor much as the growth hormone-releasing peptides do, and has never been approved for any indication. Orforglipron, a non-peptide oral GLP-1 receptor agonist, reached phase 3 in obesity and type 2 diabetes.

Crossing from peptide to mimetic changes pharmacological class, not just dosage form. Hepatic metabolism and cytochrome-mediated interactions become relevant where renal filtration and proteolysis were, immunogenicity risk generally falls, and the filing shifts toward a small-molecule pathway. What often does not survive is selectivity, since a scaffold optimised for one pocket may fit several.

The label is abused in marketing, where any short synthetic peptide is called a mimetic of something. A peptidomimetic is defined by what it replaces, so the claim means little without the parent peptide, the mimicked element and functional evidence. The other error is assuming a mimetic inherits the parent's full pharmacology; matching one binding assay does not reproduce a downstream profile.